Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

While Illumina completed the takeover of Grail last September, it has maintained the business as a separate subsidiary company while it waits for the outcome of antitrust reviews in the US and Europe.

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

GRAIL is advancing blood-based cancer detection with Galleri. Find out why GRAL stock’s future hinges on successful trials and regulatory approval.

Shares of Grail, a maker of early-detection cancer screening tests, soared last week. Here are the key chart levels to watch.

ILMN reported fourth-quarter 2024 adjusted earnings per share (EPS) of 86 cents, which missed the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line was significantly above the year-ago ...

Grail spun off from Illumina last year, and is developing a number of early detection cancer screening products. Last week, Grail said it sees fiscal 2025 sales of its Galleri blood test up 20% to ...

Illumina's (ILMN) stock slid 5% post-market after it released its Q4 earnings report and reiterated its 2025 guidance, ...

Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024 ...

Caprock Group LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 3.7% in the 4th quarter, according to the ...

Please be advised that today's conference is being recorded. I would now like to hand the conference over to Sally Schwartz, Vice President of Investor Relations. Hello everyone and welcome to our ...